Drug intelligence / Profile preview

C-1-144

Development stage: Preclinical
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

C-1-144 is an allogeneic, "universal" chimeric antigen receptor (CAR) cell therapy currently in preclinical development by Chongqing Precision Biotech Co., Ltd. The product is engineered using the company's proprietary LstCAR platform, which aims to produce off-the-shelf cell therapies that can be administered to multiple patients without the need for patient-specific manufacturing. While the specific antigen target and intended clinical indications for C-1-144 have not been publicly disclosed, the program is part of a broader pipeline focused on advancing next-generation cell-based immunotherapies.

Beyond the preview

Go deeper on C-1-144.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-1-144.

Explore the full profile